MAPK/ERK and JAK-STAT Signaling in 4R-Tauopathies

MAPK/ERK and JAK-STAT Signaling in 4R-Tauopathies

Overview

The MAPK (Mitogen-Activated Protein Kinase) and JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) signaling pathways represent critical stress-responsive cascades that are dysregulated across all 4R-tauopathies. These pathways serve as central hubs where tau pathology intersects with neuroinflammation, oxidative stress, and neuronal survival decisions. Their activation patterns differ substantially between diseases, offering mechanistic insights and therapeutic targeting opportunities.

Introduction

The MAPK family comprises three major subfamilies: ERK1/2 (extracellular signal-regulated kinases), JNK (c-Jun N-terminal kinases), and p38 MAPK. Each subfamily is activated by distinct upstream signals and elicits specific cellular responses. Similarly, the JAK-STAT pathway, primarily associated with cytokine signaling, has emerged as a key player in the neuroinflammatory response to tau pathology.

In 4R-tauopathies, these pathways serve a dual role: they mediate protective stress responses when transiently activated, but become pathogenic when chronically activated by ongoing tau pathology, neuroinflammation, and oxidative stress. The balance between protective and destructive activation of these cascades is a critical determinant of neuronal fate.

MAPK Signaling Cascades

ERK1/2 Pathway

MAPK/ERK and JAK-STAT Signaling in 4R-Tauopathies

Overview

The MAPK (Mitogen-Activated Protein Kinase) and JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) signaling pathways represent critical stress-responsive cascades that are dysregulated across all 4R-tauopathies. These pathways serve as central hubs where tau pathology intersects with neuroinflammation, oxidative stress, and neuronal survival decisions. Their activation patterns differ substantially between diseases, offering mechanistic insights and therapeutic targeting opportunities.

Introduction

The MAPK family comprises three major subfamilies: ERK1/2 (extracellular signal-regulated kinases), JNK (c-Jun N-terminal kinases), and p38 MAPK. Each subfamily is activated by distinct upstream signals and elicits specific cellular responses. Similarly, the JAK-STAT pathway, primarily associated with cytokine signaling, has emerged as a key player in the neuroinflammatory response to tau pathology.

In 4R-tauopathies, these pathways serve a dual role: they mediate protective stress responses when transiently activated, but become pathogenic when chronically activated by ongoing tau pathology, neuroinflammation, and oxidative stress. The balance between protective and destructive activation of these cascades is a critical determinant of neuronal fate.

MAPK Signaling Cascades

ERK1/2 Pathway

The ERK1/2 pathway is traditionally associated with growth factor signaling and synaptic plasticity, but in 4R-tauopathies it is frequently activated in response to tau pathology as a compensatory mechanism.

Activation Patterns

| Disease | p-ERK1/2 Level | Primary Location | Activation Trigger |
|---------|---------------|------------------|-------------------|
| PSP | Elevated | Substantia nigra, basal ganglia | Tau aggregation, oxidative stress |
| CBD | Elevated | Affected cortex | Tau pathology, neuroinflammation |
| AGD | Moderate | Limbic system | Argrophilic grains, mild stress |
| GGT | Elevated | White matter tracts | Oligodendroglial tau, myelin damage |
| FTDP-17 | Variable | Mutation-dependent | Direct tau dysfunction |

ERK1/2 and Tau Phosphorylation

ERK1/2 directly phosphorylates tau at multiple sites relevant to neurodegeneration:

• Thr181: A prominent AD phosphorylation site, also elevated in 4R-tauopathies
• Ser396/Ser404: Alzheimer-type epitopes, cross-reactive with PHF-tau
• Ser214: Associated with microtubule destabilization

Downstream Effects

• CREB activation: Leads to BDNF expression (initially compensatory)
• c-Fos induction: Alters gene expression programs
• Synaptic protein synthesis: Via Elk-1 and other transcription factors
• Cell cycle re-entry: Through cyclin D1 induction

JNK Pathway

c-Jun N-terminal kinases (JNKs) are primarily stress-activated kinases that mediate apoptosis and inflammation in tauopathies.

JNK Activation in 4R-Tauopathies

JNK is persistently activated in the brains of patients with 4R-tauopathies:

• PSP: Strong activation in basal ganglia neurons and glia
• CBD: Prominent in affected cortical neurons and astrocytes
• AGD: Moderate activation in limbic system
• GGT: Elevated in white matter tracts and affected neurons
• FTDP-17: Mutation-specific patterns

Downstream Targets

The JNK pathway is particularly implicated in the neuronal loss observed in PSP substantia nigra pars compacta, where dopaminergic neurons undergo caspase-dependent apoptosis. [@jnk_p38_2023]

p38 MAPK Pathway

p38 MAPK is strongly associated with inflammatory responses and is elevated across all 4R-tauopathies, particularly in microglia and astrocytes.

Cellular Distribution

• Microglia: Most robust p38 activation, mediating cytokine production
• Astrocytes: Moderate activation, contributing to inflammatory milieu
• Neurons: Lower but significant activation, driving stress responses

Key Targets

• p38α: Major isoform in neural cells, drives inflammatory cytokine production
• MAPKAPK-2/3: Kinases activated by p38, phosphorylate Hsp27
• C/EBP family: Transcription factors regulating inflammatory genes

JAK-STAT Signaling Pathway

Overview

The JAK-STAT pathway transduces cytokine signals through receptor-associated Janus kinases (JAK1, JAK2, JAK3, TYK2) to STAT transcription factors (STAT1, STAT2, STAT3, STAT5, STAT6).

Activation in 4R-Tauopathies

| Disease | Primary STAT | Cellular Source | Inflammatory Context |
|---------|-------------|-----------------|---------------------|
| PSP | STAT1, STAT3 | Microglia, astrocytes | IFN-γ, IL-6, IL-10 |
| CBD | STAT3 | Microglia, neurons | IL-6, CNTF, LIF |
| AGD | STAT3 | Astrocytes | Mild inflammatory milieu |
| GGT | STAT1, STAT3 | Oligodendrocytes, glia | Reactive gliosis |
| FTDP-17 | Variable | Neurons | Tau-driven inflammation |

STAT3 in Tauopathy Neuroinflammation

STAT3 is the most prominently activated STAT in 4R-tauopathies, mediating the acute phase inflammatory response:

STAT3 activation creates a feedback loop with the MAPK pathways, as IL-6 family cytokines that activate STAT3 also engage the Ras-MAPK cascade. This cross-talk amplifies inflammatory signaling. [@stat_microglia_2024]

IFN-γ/JAK/STAT1 Axis

The interferon-gamma pathway is strongly implicated in PSP:

• T cell infiltration: IFN-γ-producing T cells are found in PSP brains
• STAT1 activation: Drives expression of interferon-stimulated genes (ISGs)
• Neurotoxicity: Chronic IFN-γ signaling contributes to neuronal vulnerability

Cross-Disease Comparison

Therapeutic Targeting

MAPK Pathway Inhibitors

| Target | Compound | Development Stage | Notes |
|--------|----------|-------------------|-------|
| JNK | SP600125 | Pre-clinical | Neuroprotective in tauopathy models |
| JNK | AS601245 | Pre-clinical | Crosses BBB |
| p38α | VX-745 | Phase II (PSP) | Investigational |
| ERK1/2 | SCH772984 | Pre-clinical | Synaptic protection |
| MEK1/2 | Selumetinib | Phase II (neuro-oncology) | CNS penetration concern |

JAK-STAT Pathway Inhibitors

| Target | Compound | Development Stage | Notes |
|--------|----------|-------------------|-------|
| JAK1/2 | Ruxolitinib | Phase II (ALS) | May affect neuroinflammation |
| JAK1 | Upadacitinib | Pre-clinical | Better CNS penetration |
| STAT3 | Stattic | Pre-clinical | Direct STAT3 inhibition |
| JAK1/3 | Tofacitinib | Pre-clinical | Repurposed from rheumatology |

Cross-Disease Summary

| Pathway | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| ERK1/2 | +++ | +++ | ++ | +++ | Variable |
| JNK | +++ | ++ | + | +++ | +++ |
| p38 | +++ | +++ | ++ | +++ | ++ |
| STAT1 | +++ | ++ | + | ++ | + |
| STAT3 | +++ | +++ | ++ | +++ | Variable |
| IFN-γ axis | +++ | ++ | + | ++ | + |

Intensity: + (mild), ++ (moderate), +++ (severe)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving MAPK/ERK and JAK-STAT Signaling in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: